SK120299A3 - Use of human 'alpha'1-acid glycoprotein for producing a pharmaceutical preparation - Google Patents

Use of human 'alpha'1-acid glycoprotein for producing a pharmaceutical preparation Download PDF

Info

Publication number: SK120299A3
Authority: SK; Slovakia
Prior art keywords: use according; treatment; pharmaceutical preparation; composition; acid glycoprotein
Prior art date: 1997-03-10

Application number

SK1202-99A

Other languages

English (en)

Slovak (sk)

Inventor

Ludwig Pichler

Eva-Maria Muchitsch

Anton Philapitsch

Hans-Peter Schwarz

Yendra Linnau

Wolfgang Teschner

Original Assignee

Baxter Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-10

Filing date

1998-03-10

Publication date

2000-05-16

1998-03-10 Application filed by Baxter Ag filed Critical Baxter Ag

2000-05-16 Publication of SK120299A3 publication Critical patent/SK120299A3/sk

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims abstract 9
102000003886 Glycoproteins Human genes 0.000 title claims description 6
108090000288 Glycoproteins Proteins 0.000 title claims description 6
239000002253 acid Substances 0.000 title claims description 4
230000004089 microcirculation Effects 0.000 claims abstract description 10
230000002757 inflammatory effect Effects 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
208000035475 disorder Diseases 0.000 claims description 13
238000009472 formulation Methods 0.000 claims description 12
206010048962 Brain oedema Diseases 0.000 claims description 9
208000006752 brain edema Diseases 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 8
210000000056 organ Anatomy 0.000 claims description 7
239000002550 vasoactive agent Substances 0.000 claims description 7
206010063837 Reperfusion injury Diseases 0.000 claims description 6
230000010412 perfusion Effects 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 6
108090000623 proteins and genes Proteins 0.000 claims description 6
201000001474 proteinuria Diseases 0.000 claims description 6
206010021138 Hypovolaemic shock Diseases 0.000 claims description 5
230000017531 blood circulation Effects 0.000 claims description 5
238000001802 infusion Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
102000009027 Albumins Human genes 0.000 claims description 4
108010088751 Albumins Proteins 0.000 claims description 4
208000032843 Hemorrhage Diseases 0.000 claims description 4
208000032456 Hemorrhagic Shock Diseases 0.000 claims description 4
206010030113 Oedema Diseases 0.000 claims description 4
206010049771 Shock haemorrhagic Diseases 0.000 claims description 4
241000700605 Viruses Species 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
208000034158 bleeding Diseases 0.000 claims description 4
230000000740 bleeding effect Effects 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
230000035939 shock Effects 0.000 claims description 4
206010040560 shock Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
238000002635 electroconvulsive therapy Methods 0.000 claims description 2
238000001914 filtration Methods 0.000 claims description 2
230000002008 hemorrhagic effect Effects 0.000 claims description 2
230000000415 inactivating effect Effects 0.000 claims description 2
239000003978 infusion fluid Substances 0.000 claims description 2
229960005480 sodium caprylate Drugs 0.000 claims description 2
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 2
239000003381 stabilizer Substances 0.000 claims description 2
230000000087 stabilizing effect Effects 0.000 claims description 2
230000024883 vasodilation Effects 0.000 claims description 2
VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 claims 1
150000003943 catecholamines Chemical class 0.000 claims 1
102000012404 Orosomucoid Human genes 0.000 abstract description 2
108010061952 Orosomucoid Proteins 0.000 abstract description 2
230000004087 circulation Effects 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 34
239000000243 solution Substances 0.000 description 16
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
241000700159 Rattus Species 0.000 description 9
230000000747 cardiac effect Effects 0.000 description 9
239000000902 placebo Substances 0.000 description 9
229940068196 placebo Drugs 0.000 description 9
230000036772 blood pressure Effects 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
238000002474 experimental method Methods 0.000 description 7
230000004872 arterial blood pressure Effects 0.000 description 6
230000007423 decrease Effects 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 5
230000008081 blood perfusion Effects 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
208000028867 ischemia Diseases 0.000 description 5
238000000034 method Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
208000006011 Stroke Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
230000036513 peripheral conductance Effects 0.000 description 4
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
238000011552 rat model Methods 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
230000009471 action Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
230000002265 prevention Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
201000006474 Brain Ischemia Diseases 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
229950010131 puromycin Drugs 0.000 description 2
238000012552 review Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000012353 t test Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
RYSMHWILUNYBFW-UHFFFAOYSA-N 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(N)C1O RYSMHWILUNYBFW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010028604 Myocardial rupture Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
206010058119 Neurogenic shock Diseases 0.000 description 1
208000009893 Nonpenetrating Wounds Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
201000005180 acute myocarditis Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960000182 blood factors Drugs 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000035617 depilation Effects 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
150000008273 hexosamines Chemical class 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
238000009527 percussion Methods 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000011197 physicochemical method Methods 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035900 sweating Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
235000014101 wine Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

SK1202-99A 1997-03-10 1998-03-10 Use of human 'alpha'1-acid glycoprotein for producing a pharmaceutical preparation SK120299A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0040997A AT405241B (de)	1997-03-10	1997-03-10	Verwendung von humanem alpha1-sauren glycoprotein zur herstellung einer pharmazeutischen präparation
PCT/AT1998/000060 WO1998040087A2 (de)	1997-03-10	1998-03-10	VERWENDUNG VON HUMANEM α1-SAUREN GLYCOPROTEIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN PRÄPARATION

Publications (1)

Publication Number	Publication Date
SK120299A3 true SK120299A3 (en)	2000-05-16

Family

ID=3489866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1202-99A SK120299A3 (en)	1997-03-10	1998-03-10	Use of human 'alpha'1-acid glycoprotein for producing a pharmaceutical preparation

Country Status (14)

Country	Link
EP (1)	EP0967986B1 (da)
JP (1)	JP2001514629A (da)
AT (2)	AT405241B (da)
AU (1)	AU6284198A (da)
BR (1)	BR9808000A (da)
CA (1)	CA2283580A1 (da)
DE (1)	DE59805897D1 (da)
DK (1)	DK0967986T3 (da)
ES (1)	ES2185147T3 (da)
HU (1)	HUP0100639A3 (da)
NO (1)	NO994339L (da)
PT (1)	PT967986E (da)
SK (1)	SK120299A3 (da)
WO (1)	WO1998040087A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT408946B (de) *	1999-02-18	2002-04-25	Immuno Ag	Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation
AT407485B (de) *	1999-04-14	2001-03-26	Haemosan Erzeugung Pharmazeuti	Neue medizinische verwendung von alpha1-saurem glykoprotein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06118723A (ja) *	1992-10-02	1994-04-28	Fujitsu Ltd	電子写真用キャリア
JPH06122025A (ja) *	1992-10-14	1994-05-06	Komatsu Ltd	プレスブレーキロボットシステムのワーク曲げ追従方法

1997
- 1997-03-10 AT AT0040997A patent/AT405241B/de not_active IP Right Cessation
1998
- 1998-03-10 WO PCT/AT1998/000060 patent/WO1998040087A2/de not_active Application Discontinuation
- 1998-03-10 DE DE59805897T patent/DE59805897D1/de not_active Expired - Fee Related
- 1998-03-10 AU AU62841/98A patent/AU6284198A/en not_active Abandoned
- 1998-03-10 HU HU0100639A patent/HUP0100639A3/hu unknown
- 1998-03-10 AT AT98906744T patent/ATE225664T1/de not_active IP Right Cessation
- 1998-03-10 EP EP98906744A patent/EP0967986B1/de not_active Expired - Lifetime
- 1998-03-10 CA CA002283580A patent/CA2283580A1/en not_active Abandoned
- 1998-03-10 ES ES98906744T patent/ES2185147T3/es not_active Expired - Lifetime
- 1998-03-10 BR BR9808000-8A patent/BR9808000A/pt not_active Application Discontinuation
- 1998-03-10 JP JP53896098A patent/JP2001514629A/ja active Pending
- 1998-03-10 DK DK98906744T patent/DK0967986T3/da active
- 1998-03-10 PT PT98906744T patent/PT967986E/pt unknown
- 1998-03-10 SK SK1202-99A patent/SK120299A3/sk unknown
1999
- 1999-09-07 NO NO994339A patent/NO994339L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE59805897D1 (de)	2002-11-14
AT405241B (de)	1999-06-25
JP2001514629A (ja)	2001-09-11
WO1998040087A2 (de)	1998-09-17
BR9808000A (pt)	2000-03-08
ATE225664T1 (de)	2002-10-15
NO994339L (no)	1999-11-08
ES2185147T3 (es)	2003-04-16
WO1998040087A3 (de)	1998-12-17
DK0967986T3 (da)	2003-02-10
EP0967986A2 (de)	2000-01-05
EP0967986B1 (de)	2002-10-09
CA2283580A1 (en)	1998-09-17
PT967986E (pt)	2003-02-28
ATA40997A (de)	1998-11-15
HUP0100639A3 (en)	2001-09-28
AU6284198A (en)	1998-09-29
HUP0100639A1 (hu)	2001-08-28
NO994339D0 (no)	1999-09-07

Publication	Publication Date	Title
US6924267B2 (en)	2005-08-02	Methods and active substances for protecting organs
Ouriel et al.	1985	Protection of the kidney after temporary ischemia: free radical scavengers
AP1185A (en)	2003-07-04	Novel pharmaceutical composition for the use in emergency treatment and preparation method thereof.
JPH0348672A (ja)	1991-03-01	ラノラジンおよび関連ピペラジン誘導体を使用する新規な処置方法
Parrish et al.	2016	Cell impermeant-based low-volume resuscitation in hemorrhagic shock: a biological basis for injury involving cell swelling
KR20190105588A (ko)	2019-09-17	FXIa 항체를 위한 신규한 안정한 제제
JPH09501946A (ja)	1997-02-25	急性心筋梗塞中の心筋傷害の低減方法
Walensi et al.	2013	Mesenteric ischemia-reperfusion injury: Clearly improved hemodynamics but only minor protection of the rat small intestine by (sub) therapeutic heparin sodium and enoxaparin doses
Jin et al.	2008	The myocardial protective effects of a moderate-potassium adenosine–lidocaine cardioplegia in pediatric cardiac surgery
Hardaway	1970	The significance of coagulative and thrombotic changes after haemorrhage and injury.
Gentilini et al.	1989	Renal functional impairment and sodium retention in liver cirrhosis
SK120299A3 (en)	2000-05-16	Use of human 'alpha'1-acid glycoprotein for producing a pharmaceutical preparation
Koksal et al.	2006	Attenuation of acute lung injury following lower limb ischemia/reperfusion: the pharmacological approach
Toomayan et al.	2003	C1‐esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle
US6380254B2 (en)	2002-04-30	Method and composition for treating and preventing pathogenic effects caused by intracellular calcium overload
KR20060128972A (ko)	2006-12-14	적혈구 기능 수식 물질
US20030069174A1 (en)	2003-04-10	Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
Gosling	1999	Prevention of post-traumatic clinical capillary leak syndrome
Shin et al.	1997	Heparin attenuated neutrophil infiltration but did not affect renal injury induced by ischemia reperfusion
Gruber et al.	1992	Protracted metabolic acidosis: the impact of acute ethanol in hemorrhagic shock
Carlsson et al.	1996	Liver is not essential for solute transport during peritoneal dialysis
CZ321699A3 (cs)	2000-01-12	Použití humánního alfal-kyselého glykoproteinu k výrobě farmaceutického přípravku
CA2625888C (en)	2015-09-22	Method of treating acute renal failure with thrombomodulin variant
Sands et al.	1999	LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury
JPH08231413A (ja)	1996-09-10	臓器障害に基づく疾患の予防・治療剤